Vectura and Hikma's generic of Advair Diskus accepted for filing by US FDA

8 April 2016

Vectura Group (LSE: VEC) and Hikma Pharmaceuticals (LSE: HIK) have moved closer to US approval for a generic version of GlaxoSmithKline’s (LSE: GSK) asthma drug Advair Diskus (fluticasone propionate and salmeterol inhalation powder).

Jordan-based drugmaker Hikma acquired the VR315 product when it bought Roxane Laboratories, with whom Vectura, a UK-based developer of inhaled therapies, had been partnerning in developing the product.

VR315 is the generic version of Advair Diskus, a treatment of asthma and the maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK